| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 10mg | 电议 |
| 100mg | 电议 |
Cell lines | Neonatal rat cardiomyocytes |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 10-8 to 10-3 mol/L for 4-12 h |
Applications | Ibutilide protected against H2O2-induced cardiomyocytes injury through inhibiting endoplasmic reticulum and mitochondrial stress pathways. |
Animal models | Open-chest beagles model |
Dosage form | 10 μg/kg, intravenous administration, for 10 min; 0.1 mg/kg/h |
Applications | Ibutilide significantly decreased defibrillation threshold through the reduction of activation pattern complexity during ventricular fibrillation in canine hearts. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | Ibutilide fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.Target: Calcium ChannelIbutilide fumarate is the first 'pure' class III antiarrhythmic drug to become available. Its predominant action is prolongation of the myocardial action potential duration. Intravenous ibutilide 0.01 to 0.025 mg/kg or 1 to 2 mg successfully converted atrial flutter or fibrillation to sinus rhythm in 33 to 49% of patients in 2 placebo-controlled trials involving 439 patients with sustained arrhythmia [1]. Ibutilide fumarate appears to be an effective alternative method for rapid conversion of recent-onset AF or AFl. The drug may be particularly useful in patients who have undergone recent cardiac surgery or those who are not ideal candidates for DCC [2]. References: |
m.cnreagent.com